(AGENPARL) – SILVER SPRING mer 12 aprile 2023 The FDA’s Drug Competition Action Plan (DCAP) encourages robust and timely market competition for generic drugs and helps bring greater efficiency and transparency to the generic drug review process, without sacrificing the scientific rigor underlying our generic drug program.
Fonte/Source: http://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan